



Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

Kenjiro Aogi¹ · Kenichi Watanabe² · Masahiro Kitada³ · Takafumi Sangai⁴ · Shoichiro Ohtani⁵ · Tomoyuki Aruga⁶ · Hidetoshi Kawaguchi⁷ · Tomomi Fujisawa⁸ · Shigeto Maeda⁹ · Takashi Morimoto¹⁰ · Nobuaki Sato¹¹ · Shintaro Takao¹² · Satoshi Morita¹³ · Norikazu Masuda¹⁴ · Masakazu Toi¹⁵ · Shinji Ohno¹⁶

Published online: 27 September 2022
© The Author(s) 2022

Correction to:

International Journal of Clinical Oncology
(2021) 26:1229–1236

<https://doi.org/10.1007/s10147-021-01920-0>

In the original publication, the name of fourth and seventh authors were incorrectly published as: Takashi Sangai and Hidetoshi Kawaguchi. The correct version of names are: Takafumi Sangai and Hidetoshi Kawaguchi as given in this Correction.

The original publication has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10147-021-01920-0>.

✉ Kenjiro Aogi
aogi.kenjiro.zx@mail.hosp.go.jp

- 1 Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Kou 160, Minamiumemoto-machi, Matsuyama, Ehime 791-0280, Japan
- 2 Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
- 3 Breast Disease Center, Asahikawa Medical University Hospital, Asahikawa, Japan
- 4 Department of Breast Thyroid Surgery, Kitasato University Hospital, Sagami-hara, Japan
- 5 Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
- 6 Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
- 7 Department of Breast Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan

- 8 Department of Breast Oncology, Gunma Prefectural Cancer Center, Ohta, Japan
- 9 Department of Surgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan
- 10 Department of Breast Surgery, Yao Municipal Hospital, Osaka, Japan
- 11 Department of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan
- 12 Department of Breast Surgery, Hyogo Cancer Center Hospital, Kobe, Japan
- 13 Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- 14 Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
- 15 Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- 16 Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan